The cancer therapeutics market size is expected to reach US$ 5,31,538.02 million by 2031 from US$ 2,30,423.56 million in 2024. The market is estimated to record a CAGR of 12.8% from 2025 to 2031.

Executive Summary and Global Market Analysis

The global cancer therapeutics market is experiencing substantial growth, fueled by the escalating burden of breast and lung cancer and significant investments in oncology research. Cancer therapeutics encompasses a diverse range of treatments aimed at managing or curing cancer. Key treatment modalities include chemotherapy, radiation, immunotherapy, targeted therapy, hormone therapy, surgery, and stem cell therapy. All these strategies strive to eliminate or control cancer cells, alleviate symptoms, and enhance the overall survival of patients. Depending on the cancer type, stage, and the patient's general health, a combination of these treatments is often employed to maximize their effectiveness.

Cancer Therapeutics Market Segmentation Analysis

The derivation of the cancer therapeutics market analysis relies on key segments: therapy type, indication, and distribution channel.

By therapy type, the market is segmented into chemotherapy, targeted therapy, radiation therapy, hormone therapy, and other therapy types. Chemotherapy was the dominant segment in 2024.

In terms of indications, the market is segmented across blood cancer, lung cancer, breast cancer, colorectum cancer, prostate cancer, stomach cancer, cervical cancer, liver and intrahepatic bile duct cancer, thyroid cancer, and other indications. Lung cancer held the largest share of the market in 2024.

By distribution channel, the market is categorized into hospital pharmacies, retail pharmacies, and online stores. Hospital pharmacies maintained the largest share of the market in 2024.

Download our Sample PDF Report

@ https://www.businessmarketinsights.com/sample/BMIRE00031299

Cancer Therapeutics Market Drivers and Opportunities

As per the World Health Organization's media center, approximately 1 in every 6 deaths globally is caused by various types of cancer. In 2022, there were an estimated 20 million new cancer cases and 9.7 million deaths associated with the disease; this burden is projected to increase by roughly 77% by 2050, further straining health systems and communities. The American Cancer Society reports that 5–10% of all cancers are due to inherited genes. Numerous genes linked to cancer predisposition have been identified. For example, mutations in inherited cancer predisposition genes like BRCA1 and BRCA2 significantly increase the risk of developing breast, ovarian, and prostate cancers. Breast cancer is widely considered the most prevalent cancer among women, with its incidence continuously rising worldwide due to factors such as environmental impact, genetic susceptibility, hormone imbalances, and lifestyle changes. Furthermore, breast cancer is among the most prevalent cancers in the U.S.

About Us:

Business Market Insights is a market research platform that provides subscription service for industry and company reports. Our research team has extensive professional expertise in domains such as Electronics & Semiconductor; Aerospace & Defense; Automotive & Transportation; Energy & Power; Healthcare; Manufacturing & Construction; Food & Beverages; Chemicals & Materials; and Technology, Media, & Telecommunications